David Fajgenbaum, MD, MBA, MSc, survivor of Castleman disease and author of “Chasing My Cure,” discusses treating his own disease through experimental self-administered therapies, involvement in developing the first NCCN guidelines and FDA-approved drugs for Castleman disease, and how to effectively and systematically use off-label drugs for orphan diseases.
David’s journey is fascinating; his book is phenomenal. I even wrote a book review on the healthcare blog summarizing the lessons learned from reading it.
I learned so much from David, who also ended up delivering the keynote speech at the first ever virtual ASCO meeting that took place late May 2020. Trust me you want to listen to David, learn from him, and read his book.
This podcast is produced by the Journal of Clinical Pathways.
Dr. Pedro Barata, Director of the Clinical Genitourinary Medical Oncology Research Program at UH Seidman Cancer Center, provides an exclusive round-up of the most groundbreaking and practice-changing research unveiled at the ASCO GU 2024 meeting. With expertise and insight, he delves into pivotal studies such as CheckMate 914 Part B and KEYNOTE-564, exploring their implications
Dr. LaBelle elucidates the complexities of sickle cell disease, unraveling the devastating impact it has on individuals. The episode delves into various treatments and approaches to combat this formidable disease, including bone marrow transplant and the groundbreaking use of CRISPR-Cas9 technology. LaBelle shares insights into the recent research breakthroughs, citing the remarkable research report published
n this poignant episode, USA Today investigative journalist Emily Le Coz unravels the heart-wrenching narrative of Ashleigh Anderson, a CVS pharmacist whose tragic demise serves as a cautionary tale of overwhelming stress in the workplace. Emily shares her motivations behind delving into the pervasive issue of burnout in retail pharmacy and sheds light on the
